Biogen upgraded to Neutral from Sell at UBS
June 19, 2017 at 10:21 AM EDT
UBS analyst Carter Gould upgraded Biogen to Neutral and raised his price target for the shares to $270 from $262.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.